CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S66
DOI: 10.1055/s-0039-1685965
Abstracts
Oncology

Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs. standard follow-up in surgical resectable HNSCC after adjuvant therapy

C Betz
1   Klinik für HNO-Heilkunde, UK Hamburg-Eppendorf, Hamburg
,
M Binder
2   Universitätsklinik für Innere Medizin IV, Universitätsklinikum Halle (Saale), Halle (Saale)
,
A Münscher
1   Klinik für HNO-Heilkunde, UK Hamburg-Eppendorf, Hamburg
,
CJ Busch
1   Klinik für HNO-Heilkunde, UK Hamburg-Eppendorf, Hamburg
› Author Affiliations
Bristol-Myers Squibb
 
 

    Introduction:

    Surgically treated locally advanced head and neck squamous cell carcinoma often requires postoperative chemoradiation with high risk of acute and late toxicity. DFS after 2 years is approximately 70%. Combining anti-PD-1 and anti-CTLA4 as a maintenance therapy may improve DFS due to anti-tumor effects of immunotherapy by enhancing cross-presentation of tumor antigens.

    Methods:

    IMSTAR HN is an investigator initiated, multicenter randomized controlled phase III study. Patients with locoregionally advanced HNSCC will be randomly assigned to an experimental arm or a standard arm. Standard of care consists of surgical resection followed by risk-adapted adjuvant (chemo)radiation. In the experimental arm a single neoadjuvant dose with Nivolumab 3 mg/kg is applied. After treatment according to standard arm a second randomization will be performed: In Arm Ia Nivolumab 3 mg/kg will be given every 2 weeks until progression or up to 6 months. In Arm Ib Ipilimumab 1 mg/kg will be applied additionally every 6 weeks also until progression or up to 6 months. The primary endpoint is disease free survival at 3 years. 276 patients will be included in 10 centers in Germany. The study is accompagnied by a translational program that includes investigations concerning immunmodulation, mutational load in general, but also specific mutations in targets involved in immune function and antigen presentation. Recruitment started in August 2018. Clinical trial information: NCT03700905


    #
    Prof. Dr. med. Christian Betz
    Universitätsklinikum Hamburg-Eppendorf,
    Martinistr. 52, 20246
    Hamburg

    Publication History

    Publication Date:
    23 April 2019 (online)

    © 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York